Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 4/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488262 | 0.86 | ABL1 (0.46) | FYNAAK1HTR7BCL2L2NEK1 | |
| SCHEMBL3375853 | 0.84 | DRD4 (0.53) | CHEK1HTR7BCL2L2MAP4K1 | |
| SCHEMBL4364255 | 0.84 | FGFR2 (0.46) | FYNCDK8AAK1FGFR2NEK1 | |
| SCHEMBL12343730 | 0.83 | PDGFRB (0.50) | AAK1ABL1KIT | |
| SCHEMBL3371495 | 0.82 | NEK1 (0.60) | FYNCDK8AAK1CHEK1FGFR1 | |
| SCHEMBL11968602 | 0.82 | CDK8 (0.48) | CDK8AAK1FGFR2NEK1ABL1 | |
| SCHEMBL3373289 | 0.82 | AXL (0.55) | FYNAAK1CHEK1MAP2K4FGFR1 | |
| SCHEMBL3375663 | 0.82 | NEK1 (0.44) | AAK1NEK1ABL1MAP4K1KIT | |
| SCHEMBL11968603 | 0.82 | CDK8 (0.48) | CDK8AAK1FGFR2NEK1ABL1 | |
| SCHEMBL3490388 | 0.82 | AAK1 (0.45) | AAK1CHEK1ABL1MAP4K1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | FYN 343/4885CDK8 107/4885AAK1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.